# MAGnesium Effect With ANtiosteoporotic Drugs

> **NCT05328154** · PHASE2 · COMPLETED · sponsor: **University Hospital, Clermont-Ferrand** · enrollment: 45 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **OTHER:** Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care
- **DRUG:** Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation

## Key facts

- **NCT ID:** NCT05328154
- **Lead sponsor:** University Hospital, Clermont-Ferrand
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2024-12-19
- **Final completion:** 2024-12-19
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05328154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05328154, "MAGnesium Effect With ANtiosteoporotic Drugs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05328154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*